HCCLM6 Xenograft Model Service for Liver Cancer

The HCCLM6 cell line offers a highly aggressive and metastatic in vivo platform for investigating the molecular drivers of hepatocellular carcinoma (HCC) progression and systemic spread. As a specialized pre-clinical contract research organization, Alfa Cytology delivers an integrated, high-precision HCCLM6 Xenograft Model Service, meticulously optimized to provide reproducible, audit-ready data packages that accelerate your liver cancer drug discovery and development pipeline.

Overview of HCCLM6 Xenograft Model for Liver Cancer

The HCCLM6 xenograft model is an advanced in vivo translational system widely utilized in oncology research for studying highly invasive and metastatic hepatocellular carcinoma. Derived from an HCC patient with severe metastatic disease, the HCCLM6 model effectively reproduces aggressive primary tumor growth, rapid local invasion, and spontaneous metastatic dissemination to distant organs, including the lungs, when transplanted into immunodeficient rodent hosts.

Biologically, the HCCLM6 model is distinguished by its exceptionally high metastatic potential compared to other HCC lines, making it an ideal system for evaluating novel therapies designed to inhibit tumor cell migration, invasion, and metastatic colonization. This model maintains critical human liver cancer molecular features, including the expression of EMT (epithelial-mesenchymal transition) markers and robust responsiveness to both molecularly targeted agents and standard systemic chemotherapeutic regimens. Consequently, the HCCLM6 model is extensively deployed in pre-clinical screening programs to assess the anti-metastatic and anti-tumor potency of novel compounds in a physiologically relevant in vivo setting.

Fig 1. Screening of LNM-related circRNAs in HCC. (Yang Y, et al., 2024)

Cell Line Information: HCCLM6

The HCCLM6 cell line is a human hepatocellular carcinoma line specifically selected for its aggressive and high metastatic phenotype. These cells grow as adherent cultures under standard in vitro laboratory parameters, maintaining a stable, malignant profile suitable for sophisticated oncology research.

Our Services

Workflow of HCCLM6 Xenograft Model Construction

• Cell Culture & Quality Control: Human HCCLM6 cells are expanded in vitro using certified nutrient media under optimized physiological parameters. STR authentication and mycoplasma screening are performed prior to inoculation to ensure absolute genetic identity and purity.
• Host Selection & Preparation: Immunodeficient mice (e.g., BALB/c nude or NCG) are sourced from validated vendors and acclimatized to facility conditions to stabilize baseline biological metrics.
• Precision Inoculation: A calibrated suspension of high-viability HCCLM6 cells is prepared, often supplemented with an extracellular matrix (e.g., Matrigel) to enhance take rates. Cells are inoculated in vivo via orthotopic (intrahepatic) or subcutaneous injection methods to facilitate primary tumor development and subsequent distant metastasis.
• Longitudinal Monitoring: Primary tumor dimensions are systematically measured using digital calipers. Metastatic progression is monitored via clinical observation, and if required, endpoint imaging or histological analysis is used to quantify systemic metastatic burden.
• Randomization & Treatment: Once solid tumors reach a predefined, statistically significant volume, the animals are randomized into experimental cohorts to ensure baseline parity before the initiation of customized therapeutic dosing regimens.

Fig 2. HCCLM6 Xenograft Model Construction Workflow

Case Study - HCCLM6 Xenograft Model Development

A pre-clinical validation study was conducted using the HCCLM6 xenograft model to evaluate the therapeutic efficacy of a novel anti-metastatic inhibitor designed for hepatocellular carcinoma. Following precision inoculation of HCCLM6 cells into immunodeficient mice, the animals developed aggressive solid tumors accompanied by secondary metastatic spread. Animals assigned to the active treatment group demonstrated a statistically significant reduction in both primary tumor volume and the incidence of distant metastatic nodules compared to the vehicle control, confirming the model's high sensitivity and predictive reliability for screening targeted liver cancer therapies.

Why Choose Alfa Cytology?

• Oncology Domain Expertise: Profound experience in managing diverse solid tumor lineages, providing highly reproducible in vivo translational platforms for liver cancer research.
• Rigorous Quality Control: Meticulous cell validation and standardized operating procedures that minimize experimental variability across all project stages.
• Tailored Experimental Design: Highly flexible protocols that adapt to specific animal strain requirements, custom dosing schedules, and unique compound properties.
• High-Resolution Deliverables: Every project concludes with a detailed, audit-ready report providing comprehensive tumor growth metrics and statistical validations.

Contact us

Accelerating your liver cancer drug pipeline requires a pre-clinical partner with the technical proficiency to execute rigorous in vivo workflows flawlessly. If you are looking to advance your novel compound or require specialized pre-clinical testing using our HCCLM6 platform, please reach out to us today to discuss your project requirements with our expert scientific team.

For research use only. Not intended for any clinical use.